Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosen, D. G.
Right arrow Articles by Liu, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosen, D. G.
Right arrow Articles by Liu, J.
Clinical Cancer Research Vol. 11, 632-637, January 2005
© 2005 American Association for Cancer Research

Imaging, Diagnosis, Prognosis

Subcellular Localization of p27kip1 Expression Predicts Poor Prognosis in Human Ovarian Cancer

Daniel G. Rosen1, Gong Yang1, Kathy Qi Cai1, Robert C. Bast, Jr.2, David M. Gershenson3, Elvio G. Silva1 and Jinsong Liu1

Departments of 1 Pathology, 2 Experimental Therapeutics, and 3 Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Jinsong Liu, Department of Pathology, Unit 85, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095. Phone: 713-745-1102; Fax: 713-792-5529; E-mail: jliu{at}mdanderson.org.


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: The cyclin-dependent kinase inhibitor p27kip1 regulates cellular progression from G1 to S phase. Several studies have shown that loss of p27kip1 protein expression is associated with disease progression in various malignancies. The purpose of this study was to evaluate the subcellular localization of this cyclin-dependent kinase inhibitor in a large cohort of primary ovarian carcinomas and compare the results with clinicopathologic variables and overall survival.

Experimental Design: Subcellular localization of p27kip1 was first assessed by Western blotting in nuclear and cytoplasmic extract from 13 cases of ovarian carcinoma. Subcellular localization of the p27kip1 protein was evaluated using tissue microarrays containing 421 cases of ovarian carcinoma.

Results: The presence of p27kip1 in the cytoplasm regardless of the nuclear stain correlated strongly with late-stage disease (P < 0.03), extent of cytoreduction (P = 0.03), and shorter disease-specific survival (P < 0.0001).

Conclusion: Cytoplasmic localization of p27kip1 predicts poorer prognosis in ovarian carcinoma, particularly in late-stage disease.

Key Words: p27kip1 • tissue microarray; prognostic marker • prognostic marker • ovarian cancer


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Human ovarian cancer is the fifth leading cause of death among women in the United States. The wide variability in response to treatment reflects the heterogeneity in tumor histotype and grade as well as the nonspecific nature of the symptoms associated with early-stage disease. The most consistently reported significant prognostic indicators for human ovarian cancer are disease stage, tumor grade, histotype, and extent of surgical cytoreduction. Although these factors are not always related to the biological behavior or aggressiveness of the disease, they are used as guidelines for selecting anticancer therapy (1). There is a wide spectrum of clinical behaviors from an excellent prognosis and a high likelihood of cure to those with rapid progression and poor prognosis irrespective of the clinical stage of the disease, most probably reflecting different biological properties of the tumors.

Cellular progression through the cell cycle is governed by cyclin-dependent kinase (cdk) that is regulated by phosphorylation, activated by binding of cyclins, and inhibited by cdk inhibitors. Based on their protein sequence homologies and putative cdk targets, cdk inhibitors belong to one of two families: the CIP/KIP family (p21Waf1/Cip1, p27kip1, and p57kip2), which inhibits a broad range of cyclin/cdk complexes and the INK4 family (p15Ink4b, p16Ink4a, p18Ink4c, and p19Ink4d), which inhibit mainly cdk4 and cdk6. The coordinated expression of cyclins, cdks, and cdk inhibitors is often deregulated in cancer (2). The cdk inhibitor p27kip1 regulates cellular progression from G1 to S phase. p27kip1 acts primarily by complexing with cyclins D1 and E, thereby inhibiting the function of these cdks. Several studies have shown that loss of p27kip1 protein expression is associated with disease progression in various malignancies (3–5) and with poor prognosis in prostate and colon cancer (4, 6). In breast cancer, the appearance of p27kip in the cytoplasm of tumor cells is associated with poor prognosis (3, 7). However, it is still controversial whether expression or loss of expression of p27kip1 has any prognostic significance in human ovarian cancer (7–11). In addition, the prognostic significance of subcellular localization has not been previously investigated. In this paper, we addressed this question by evaluating the subcellular localization of p27kip1 and its expression using tissue microarrays from 441 patients with ovarian cancer.


   PATIENTS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients. Samples from women with primary epithelial ovarian cancer who had undergone initial surgery at the University of Texas M.D. Anderson Cancer Center between 1990 and 2001 were included in this study. A total of 441 correlative patients were identified. Follow-up information was updated through June 2003 by reviewing medical records and the U.S. Social Security Index. Demographic and survival data were entered into a comprehensive database created with Microsoft Access (version 97). Histopathologic diagnoses were based on WHO criteria (12–16); tumor grade based on Gynecologic Oncology Group criteria (17) and each case was assigned a disease stage according to the International Federation of Gynecology and Obstetrics system (18). Disease-specific survival rates were calculated as the percentage of subjects who survived with disease for a defined period, reported as time since diagnosis or treatment, and only deaths from the disease were counted. The extent of cytoreduction was defined as optimal if residual disease after surgery was smaller than 1 cm or suboptimal if residual disease was larger than 1 cm. (19, 20). Use of tissue blocks and chart review was approved by appropriate institutional committee.

Nuclear and Cytoplasmic Extraction. Ten cases of primary ovarian carcinoma were selected for Western blot analysis. Frozen sections were prepared and evaluated before processing to ensure correct sampling of the tumor and that at least 200 µg of pure tumor tissue (>80% tumor) had been collected from each case. The tissue samples were then homogenized in 500 µL of homogenizing buffer [10 mmol/L HEPES, 1.5 mmol/L MgCl2, 10 mmol/L KCl, 0.3 mmol/L sucrose, 0.1 mmol/L EGTA, 0.5 mmol/L DTT, 0.5 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L sodium orthovanadate, 1 µg/mL pepstain, 5 µg/mL leupeptin, 0.15 unit/mL aprotinin, 1 mmol/L sodium fluoride, and 0.1% NP40 (pH 7.9)] using a Polytron microprobe set at "7" for 30 seconds on ice. The product was centrifuged at 3,000 rpm for 20 minutes at 4°C, after which the supernatant was transferred to a new tube and ultracentrifuged again at 20,000 rpm for 2 hours at 4°C. The supernatant was transferred to another new tube and used for cytoplasmic fraction analyses. The pellet was washed thrice with homogenizing buffer, 50 µL of nuclear extract buffer was added [20 mmol/L HEPES, 420 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.2 mmol/L EDTA, 0.1 mmol/L EGTA, 25% glycerol, 1 mmol/L DTT, 0.5 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L sodium orthovanadate, 1 µg/mL pepstain, 5 µg/mL leupeptin, 0.15 unit/mL aprotinin, and 0.5 mmol/L spermidine (pH 7.9)], and the pellet was dispersed by gentle mixing for 1 hour on ice and centrifuged at 5,000 rpm for 10 minutes at 4°C. The supernatant was dialyzed against homogenizing buffer for 2 hours at 4°C. The resultant supernatant was transferred to a new tube and used for nuclear fraction analyses.

Western Blotting. Equal amounts of proteins (about 50 µg) were analyzed using standard methods for protein electrophoresis and transfer. The primary antibodies were to p27kip1 (clone 57, BD PharMingen, San Diego, CA), c-myc (Zymed Biotech, San Francisco, CA), ß-actin (Sigma Chemicals, St Louis, MO). The secondary antibodies were against mouse or rabbit IgGs (Amersham Biosciences, Piscataway, NJ). The detection reagents were from an electrochemiluminescence kit (Amersham Biosciences). The adequacy of nuclear and cytoplasmic extracts was confirmed by using antibodies against c-myc (for nuclear samples) and ß-actin (for cytoplasmic samples).

Construction of the Tissue Microarrays. Tissue blocks were stored under ambient conditions, at ~24°C. H&E-stained sections were reviewed by a pathologist to select representative areas of tumor from which to acquire cores for microarray analysis. Tissue microarray blocks were constructed by taking core samples from morphologically representative areas of paraffin-embedded tumor tissues and assembling them on a recipient paraffin block. This was done with a precision instrument (Beecher Instruments, Silver Spring, MD) that uses two separate core needles for punching the donor and recipient blocks and a micrometer-precise coordinate system for assembling tissue samples on a block. For each case, two replicate 1-mm core diameter samples were collected and each was placed on a separate recipient block. The final tissue microarray consisted of six blocks, the first pair (blocks 1a and b) containing duplicates of 158 spots, the second pair (2a and b) containing duplicates of 164 spots, and the third pair containing duplicates of 119 spots. All samples were spaced 0.5 mm apart. Five-micrometer sections were obtained from the microarray and stained with H&E to confirm the presence of tumor and to assess the tumor histology. Tumor samples were randomly arranged on the blocks.

Sample tracking was based on coordinate positions for each tissue spot in the tissue microarray block; the spots were transferred onto tissue microarray slides for staining. This sample tracking system was linked to a Microsoft Access database containing demographic, clinicopathologic, and survival data on each patient, thereby allowing rapid links between histologic data and clinical features. The array was read according to the given tissue microarray map, each core was scored individually, and the results were presented as the mean of the two replicate core samples. Cases in which no tumor was found or no cores were available were excluded from the final data analysis.

Immunohistochemical Analysis. The tissue microarray slides were subjected to immunohistochemical staining as follows. After initial deparaffinization, endogenous peroxidase activity was blocked by using 0.3% H2O2. Deparaffinized sections were microwaved in 10 mmol/L citrate buffer (pH 6.0) to unmask the epitopes. The slides were then incubated for 1 hour at room temperature using the same antibody against p27kip1 used for western blot analysis (1:100, clone 57, BD PharMingen), next with biotin-labeled secondary antibody for 20 minutes, and finally with a 1:40 solution of streptavidin-peroxidase for 20 minutes. Tissues were then stained for 5 minutes with 0.05% 3',3-diaminobenzidine tetrahydrochloride that had been freshly prepared in 0.05 mol/L Tris buffer at pH 7.6 containing 0.024% H2O2 and then counterstained with hematoxylin, dehydrated, and mounted. All of the dilutions of antibody, biotin-labeled secondary antibody, and streptavidin-peroxidase were made in PBS (pH 7.4) containing 1% bovine serum albumin. Colon carcinoma was used as a positive control. Negative controls were made by replacing the primary antibody with PBS. All controls gave satisfactory results.

The immunostained slides were reviewed by two pathologists, who followed the tissue microarray map to record a score for each sample. Each reviewer was blinded to the other's assessment and to clinicopathologic information. Scoring discrepancies (11 cases, 3%), were resolved by a third pathologist. p27kip1 expression was graded semiquantitatively by the reviewers. The scoring system was based on the subcellular localization of the p27kip1 negative, nuclear, or cytoplasmic (21). The cytoplasmic and nuclear stains were scored separately, not additively. Negative staining was defined as absence of cytoplasmic stain and <5% of positive nuclei. Cytoplasmic staining was scored on a three-point system based on intensity: negative (no stain), weakly positive (1+), and strongly positive (2+). When staining was present in the nucleus but not in the cytoplasm, the sample was scored as "nuclear staining only." Nuclear staining was judged to be positive if >5% nuclei in the sample were stained and negative if <5% of the nuclei stained. Ten high-power fields were examined. Normal ovarian epithelial cells were used as a comparison for intensity and pattern of staining. The mean of the results from the two replicate core samples from each tumor specimen was considered for each case.

Statistical Analysis. Differences in proportions were evaluated by the {chi}2 or Fisher's exact test as appropriate. Kruskal-Wallis test was used to compare multiple independent samples on the tissue microarray block containing normal ovary and the different ovarian tumors. Also, differences in expression levels between normal ovarian epithelial cells and the different ovarian tumors was calculated using Mann-Whitney U test. These results were adjusted for multiple comparisons and considered statistically significant at the P < 0.01 level. Disease-specific survival rates were calculated using the method of Kaplan and Meier and compared by the log-rank test. Cox proportional hazards regression models were used for multivariate analysis of survival. Statistica software was used for the statistical analysis (SAS Institute, SAS Language Reference, version 8, SAS Institute, Inc., Cary, NC, 1999). Results were considered statistically significant at the P < 0.05 level.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Patient Characteristics. The mean age of the 441 patients was 58.2 years (range, 20-96 years). With regard to surgical disease stage, 36 patients (8.1%) had stage I disease, 32 (7.2%) had stage II disease, 291 (65.9%) had stage III disease, and 82 (18.5%) had stage IV disease. The tumor histotype was serous carcinoma in 336 patients (76.2%), endometrioid in 41 (9.3%), clear cell in 18 (4.1%), mixed malignant mullerian tumor in 17 (3.9%), undifferentiated carcinoma in 12 (2.7), mucinous in 10 (2.3%), and transitional cell carcinoma in 7 (1.6%). The mean follow-up interval was 64 months (range, 1-120 months), and the overall survival rate at 5 years was 38%.

Validation of p27kip Antibody. To determine the prognostic significance of p27kip1 according to its subcellular localization, we first validated the antibody with Western blotting in nuclear and cytoplasmic extracts from 13 randomly selected cases of ovarian carcinoma (Fig. 1). Using the same antibody, we immunostain whole sections of the same 13 cases and compared the results with the Western blot. The Western blots showed high expression of p27kip1 in the nucleus in three cases (cases 2, 9, and 13) and in both the nucleus and cytoplasm in the remaining 10 cases. Immunohistochemical analysis of whole sections from the same 13 cases showed similar results, the example photomicrographs of immunohistochemical staining for case 2 (nuclear only) and case 8 in nuclear and cytoplasmic extracts are shown in Fig. 1. In the five control cases (normal ovarian surface epithelium), only nuclear staining for p27kip1 was observed (Fig. 1B, 3). Antibodies to c-myc (which is present only in the nucleus) and ß-actin (which is present only in the cytoplasm) confirmed the proper preparation of the nuclear and cytoplasmic extracts.




View larger version (92K):
[in this window]
[in a new window]
  		Fig. 1 Western blot analysis and immunohistochemical stains for p27kip1. A, Western blot of nuclear (N) and cytoplasmic (C) extracts in 13 cases of ovarian carcinoma. C-myc and ß-actin were used to determine the adequacy of the nuclear and cytoplasmic extracts. Above each band, localization according to immunohistochemical results. B, immunohistochemical stains of the same 13 cases. 1, nuclear-only staining for p27kip1 corresponding to case 2 (black arrows); 2, cytoplasmic staining (black arrows) in a high-grade serous carcinoma (case 8); 3, normal ovarian surface epithelium showing only nuclear stain (black arrows, 40x magnification).

 
P27kip1 Subcellular Localization and Its Association with Disease Stage, Tumor Grade, Patient's Age, and Level of Cytoreduction. Of all 441 cases identified, 421 (95.4%) could be scored for p27kip1 staining; the remaining cases were either lost during the sectioning procedure or did not meet the criteria for inclusion. Results from immunostaining of the microarrays, presented according to clinicopathologic characteristics of the patients, are shown in Table 1. p27kip1 protein was observed in the nucleus only in 122 cases (29%), in both the nucleus and the cytoplasm in 240 cases (57%) and negative expression in 59 of the cases (14%). With regard to the cytoplasmic intensity staining, 96 cases showed weak intensity and 144 cases strong intensity. No difference was found in the association with clinical variables between the weakly and strongly positive cytoplasmic staining groups (data not shown). Therefore, additional analysis was done between negative, cytoplasmic and nuclear localization.


View this table:
[in this window]
[in a new window]
  		Table 1 Localization of p27kip1 in terms of patient and tumor characteristics

 
Subcellular localization of p27kip1 was increasingly more common in later-stage disease (P < 0.03). Concomitantly, nuclear-only expression was more common in early-stage disease (Table 1). No difference was observed in tumor grade, histotype or patient's age at time of diagnosis between negative, cytoplasmic, or nuclear localization. Expression of p27kip1 only in the nucleus correlated with optimal levels of cytoreduction (P = 0.03). In contrast, cases showing either negative expression or cytoplasmic localization of p27kip1 had suboptimal cytoreduction.

p27kip1 Subcellular Expression and Its Association with Disease-Specific Survival. Overall ovarian cancer–specific survival times and rates at 2 and 5 years are shown in relation to the subcellular localization of p27kip1 protein in Table 2. Among all patients, the subcellular localization of p27kip1 significantly influenced disease-specific survival (P < 0.0001; Fig. 2A). Patients with tumors that expressed p27kip1 only in the nucleus had better survival, in terms of both rate and duration, than did patients with cytoplasmic or no p27kip1 expression. Moreover, this difference was also evident within certain well-defined clinical groups belonging to the same clinical stage. Among 355 late-stage disease patients, those with nuclear only expression of p27kip1 had a better overall survival than those with negative or cytoplasmic localization of the marker (P = 0.0002). A trend to better survival in cases with nuclear expression was also observed on early-stage disease group (P = 0.06).


View this table:
[in this window]
[in a new window]
  		Table 2 p27kip1 localization and overall disease-specific survival

 


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 2 Association of p27kip1 subcellular localization on overall survival in ovarian carcinoma. A, p27kip1 localization in all ovarian cancer cases; B, late-stage disease cases (Kaplan-Meier analysis).

 
We used a multivariate regression analysis based on the Cox proportional hazard model to test the independent value of each variable predicting overall survival among all patients and on those with late-stage disease. The estimated prognostic value of each variable in relation to overall survival is expressed as a P value. The variables used in Cox regression analysis are shown in Table 3. Subcellular localization of p27kip1 was an independent prognostic factor for poor survival among all patients (P = 0.0007; hazard ratio, 1.7; 95% confidence interval, 1.2-2.3) and also in those with late-stage disease (P = 0.001; hazard ratio, 1.6; 95% confidence interval, 1.2-2.2). Other independent prognostic factors associated with poor prognosis were International Federation of Gynecology and Obstetrics stage, age at diagnosis >60 years, and extent of cytoreduction.


View this table:
[in this window]
[in a new window]
  		Table 3 Univariate and multivariate analysis of factors predictive of death from disease and in late-stage disease in ovarian carcinoma

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this large study of 421 patients with primary ovarian cancer with long-term follow-up available, we analyzed the prognostic significance of p27kip1 subcellular localization in terms of survival and its association with clinicopathologic variables. p27kip1 has been considered as a tumor suppressor gene and loss of its function has been associated with development of many types of human cancer. The tumor suppressor function of p27kip1 was first implicated in the context of cell cycle regulation (2). Recent studies showed that oncogenically activated kinase Akt/PKB can also phosphorylate p27kip1 at T157 inducing its relocalization to the cytoplasm (22, 23). Akt-mediated cytosolic accumulation of p27kip1 is critical for Akt mitogenic signaling. Akt-mediated exclusion of wild-type p27kip1 from the nuclear compartment results in activation of nuclear cdk2 and cell cycle progression, whereas a mutation at T157 confers resistance to Akt-mediated p27kip1 nuclear exclusion and impairs Akt-dependent rescue of p27kip1 induced cell cycle arrest (7). Hence, sufficient evidence has accumulated to suggest that cytoplasmic relocalization of p27kip1 might facilitate the tumor development. The presence of cytoplasmic p27kip1 (induced by phosphorylation at T157) has been shown to predict poor prognosis in breast cancer (22, 23) .

Other studies have also analyzed the relationship of p27kip1 in ovarian carcinoma with survival using different scoring systems to quantify its expression (8–11, 24, 25). In two studies of 66 and 99 cases and scoring all immunoreactive cells regardless the subcellular localization, Masciullo et al. (8, 9) described that p27kip1 is an independent prognostic factor of disease progression and survival; however, no correlation with other clinicopathologic variables was found. Scoring the frequency of only nuclear immunopositive cells in a series of 54 patients (30 long-term and 24 short-term survivors), Newcomb et al. (10) also reached to similar conclusions. Hurteau et al. (21) found that decreased nuclear staining of p27kip1 was associated with poor survival in some epithelial ovarian cancers. In another study including 79 cases of ovarian carcinoma, Shigemasa et al. did not find an effect on prognosis. However, they did found a prognostic significance when only the serous carcinomas cases were studied (24). The only other study that showed lack of prognostic significance is the one from Baekelandt et al. (11). These diverse results probably reflect differences in the number of subjects, study design, and protein quantification methods among these studies, in particular specificity of antibodies.

In this study, we first validate the specificity of the antibodies used to detect the expression of subcellular localization on immunohistochemistry. Using this validated antibody, we have shown that the nuclear only expression of p27kip1 is a favorable prognostic marker (21). However, the most interesting results from our study, and one that differs from all previous ones, was the association between cytoplasmic localization of p27kip1 and prognosis in human ovarian cancer. The presence of p27kip1 in the cytoplasm and regardless of the nuclear expression correlated with higher International Federation of Gynecology and Obstetrics disease stage (P < 0.03), with extent of cytoreduction (P < 0.03), and with shorter disease survival (P < 0.0001). By analyzing the subcellular localization of this cdk inhibitor, we were able to identify a subset of patients with particularly poor outcome. Using the Cox proportional hazard model of factors influencing survival, we could also show the prognostic independence of p27kip1 in both groups, one including all the patients and in the other only those with late-stage disease. However, the underlying mechanism of why patients with negative and cytoplasmic relocalization of p27kip1 have poor prognostic significance is not clear and will require further investigation.

In conclusion, p27kip1 subcellular location in the cytoplasm was independently associated with poorer survival among women with ovarian carcinoma, particularly for those with late-stage disease and regardless of tumor histotype.


   FOOTNOTES
 
Grant support: American Society Research Scholar grant RSG-04-028-1-CCE and National Cancer Institute Institutional Research grant P01CA64602-1, and M.D. Anderson Cancer Center SPORE (J. Liu).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 6/18/04; revised 8/24/04; accepted 10/13/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ozols RF. Update on the management of ovarian cancer. Cancer J 2002;8:22–30.
  2. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995;5:127–56.[Medline]
  3. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227–30.[CrossRef][Medline]
  4. Cote RJ, Shi Y, Groshen S, et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90:916–20.[Abstract/Free Full Text]
  5. Sgambato A, Migaldi M, Faraglia B, et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 1999;59:3245–50.[Abstract/Free Full Text]
  6. Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313–23.[Abstract/Free Full Text]
  7. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136–44.[CrossRef][Medline]
  8. Masciullo V, Sgambato A, Pacilio C, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999;59:3790–4.[Abstract/Free Full Text]
  9. Masciullo V, Ferrandina G, Pucci B, et al. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res 2000;6:4816–22.[Abstract/Free Full Text]
  10. Newcomb EW, Sosnow M, Demopoulos RI, et al. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 1999;154:119–25.[Abstract/Free Full Text]
  11. Baekelandt M, Holm R, Trope CG, Nesland JM, Kristensen GB. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res 1999;5:2848–53.[Abstract/Free Full Text]
  12. Russell P, Painter DM. The pathological assessment of ovarian neoplasms V: the germ cell tumours. Pathology 1982;14:47–72.[Medline]
  13. Gee DC, Russell P. The pathological assessment of ovarian neoplasms. IV. The sex cord-stromal tumours. Pathology 1981;13:235–55.[Medline]
  14. Russell P. The pathological assessment of ovarian neoplasms. III: the malignant "epithelial" tumours. Pathology 1979;11:493–532.[Medline]
  15. Russell P. The pathological assessment of ovarian neoplasms. II: the proliferating "epithelial" tumours. Pathology 1979;11:251–82.[CrossRef][Medline]
  16. Russell P. The pathological assessment of ovarian neoplasms. I. Introduction to the common "epithelial" tumours and analysis of benign "epithelial" tumours. Pathology 1979;11:5–26.[Medline]
  17. Benda JA, Zaino R. Pathology manual. Buffalo (NY): Gynecologic Oncology Group; 1995.
  18. Cancer Committee of the International Federation of Gynecology and Obstetrics. FIGO Cancer Committee. Gynecol Oncol 1986;25:383–5.[CrossRef]
  19. Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994;55:91–6.[CrossRef][Medline]
  20. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974–9.[Medline]
  21. Hurteau JA, Allison BM, Brutkiewicz SA, et al. Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in epithelial ovarian cancer. Gynecol Oncol 2001;83:292–8.[CrossRef][Medline]
  22. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145–52.[CrossRef][Medline]
  23. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002;8:1153–60.[CrossRef][Medline]
  24. Shigemasa K, Shiroyama Y, Sawasaki T, et al. Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas. Int J Oncol 2001;18:953–8.[Medline]
  25. Sui L, Tokuda M, Ohno M, Hatase O, Hando T. The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol 1999;73:202–9.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. Denicourt, C. C. Saenz, B. Datnow, X.-S. Cui, and S. F. Dowdy
Relocalized p27Kip1 Tumor Suppressor Functions as a Cytoplasmic Metastatic Oncogene in Melanoma
Cancer Res., October 1, 2007; 67(19): 9238 - 9243.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A. Besson, H. C. Hwang, S. Cicero, S. L. Donovan, M. Gurian-West, D. Johnson, B. E. Clurman, M. A. Dyer, and J. M. Roberts
Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype
Genes & Dev., July 15, 2007; 21(14): 1731 - 1746.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Goyeneche, R. W. Caron, and C. M. Telleria
Mifepristone Inhibits Ovarian Cancer Cell Growth In vitro and In vivo
Clin. Cancer Res., June 1, 2007; 13(11): 3370 - 3379.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Yang, D. G. Rosen, Z. Zhang, R. C. Bast Jr., G. B. Mills, J. A. Colacino, I. Mercado-Uribe, and J. Liu
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis
PNAS, October 31, 2006; 103(44): 16472 - 16477.
[Abstract] [Full Text] [PDF]

Home page
 Plant Physiol.Home page
M. J. Jakoby, C. Weinl, S. Pusch, S. J.H. Kuijt, T. Merkle, N. Dissmeyer, and A. Schnittger
Analysis of the Subcellular Localization, Function, and Proteolytic Control of the Arabidopsis Cyclin-Dependent Kinase Inhibitor ICK1/KRP1
Plant Physiology, August 1, 2006; 141(4): 1293 - 1305.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosen, D. G.
Right arrow Articles by Liu, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosen, D. G.
Right arrow Articles by Liu, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online